BIOMAT Database Logo BIOMAT Database Logo

Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. 1993

A D Seidman, and L Norton, and B S Reichman, and J P Crown, and T J Yao, and R Heelan, and T B Hakes, and D E Lebwohl, and T A Gilewski, and A Surbone
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

Single-agent paclitaxel (TAXOL) was administered to 79 patients with stage IV breast cancer. Twenty-eight patients had no prior chemotherapy (for metastatic disease), and 51 patients had extensive exposure to other chemotherapeutic agents before beginning the 24-hour paclitaxel infusion. Routine use of recombinant human granulocyte colony-stimulating factor helped to ameliorate neutropenia, the dose-limiting toxicity, in some cases. Other toxicity was generally mild to moderate. Paclitaxel was more active in patients whose stage IV disease had not yet been exposed to chemotherapy, but activity was seen in the patients previously treated extensively as well. There is a strong clinical suggestion of non-cross-resistance with doxorubicin. In one case, an excellent response in previously irradiated skin was seen. Paclitaxel is a very promising agent for the treatment of metastatic breast cancer.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

A D Seidman, and L Norton, and B S Reichman, and J P Crown, and T J Yao, and R Heelan, and T B Hakes, and D E Lebwohl, and T A Gilewski, and A Surbone
Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report.
January 1993, Journal of the National Cancer Institute. Monographs,
A D Seidman, and L Norton, and B S Reichman, and J P Crown, and T J Yao, and R Heelan, and T B Hakes, and D E Lebwohl, and T A Gilewski, and A Surbone
Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor.
April 1989, Seminars in hematology,
A D Seidman, and L Norton, and B S Reichman, and J P Crown, and T J Yao, and R Heelan, and T B Hakes, and D E Lebwohl, and T A Gilewski, and A Surbone
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
October 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A D Seidman, and L Norton, and B S Reichman, and J P Crown, and T J Yao, and R Heelan, and T B Hakes, and D E Lebwohl, and T A Gilewski, and A Surbone
Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer.
January 1993, Journal of the National Cancer Institute. Monographs,
A D Seidman, and L Norton, and B S Reichman, and J P Crown, and T J Yao, and R Heelan, and T B Hakes, and D E Lebwohl, and T A Gilewski, and A Surbone
Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor.
June 1999, Breast cancer research and treatment,
A D Seidman, and L Norton, and B S Reichman, and J P Crown, and T J Yao, and R Heelan, and T B Hakes, and D E Lebwohl, and T A Gilewski, and A Surbone
Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report.
November 1993, Annals of the New York Academy of Sciences,
A D Seidman, and L Norton, and B S Reichman, and J P Crown, and T J Yao, and R Heelan, and T B Hakes, and D E Lebwohl, and T A Gilewski, and A Surbone
Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report.
February 1989, The American journal of medicine,
A D Seidman, and L Norton, and B S Reichman, and J P Crown, and T J Yao, and R Heelan, and T B Hakes, and D E Lebwohl, and T A Gilewski, and A Surbone
Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
November 1996, British journal of cancer,
A D Seidman, and L Norton, and B S Reichman, and J P Crown, and T J Yao, and R Heelan, and T B Hakes, and D E Lebwohl, and T A Gilewski, and A Surbone
Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
January 1997, British journal of cancer,
A D Seidman, and L Norton, and B S Reichman, and J P Crown, and T J Yao, and R Heelan, and T B Hakes, and D E Lebwohl, and T A Gilewski, and A Surbone
Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha.
April 1995, Journal of medical virology,
Copied contents to your clipboard!